Argent Trust Co Increases Position in Johnson & Johnson $JNJ

Key Points

• Argent Trust Co. increased its Johnson & Johnson position by 6% in the second quarter, adding 10,773 shares for a total of 191,349 shares valued at approximately $48.6 million. Institutional investors collectively own 69.55% of J&J.
• Johnson & Johnson beat quarterly expectations, reporting adjusted earnings of $2.90 per share and revenue of $25.31 billion, with revenue up 6.6% year over year. The company maintained fiscal 2026 guidance of $11.60–$11.75 in EPS.
• The company declared a quarterly dividend of $1.34 per share, equivalent to an annualized $5.36 payout and a 2.0% yield. Analysts have a “Moderate Buy” consensus rating with an average price target of $268.22.

Argent Trust Co lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 6.0% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 191,349 shares of the company's stock after acquiring an additional 10,773 shares during the quarter. Johnson & Johnson accounts for about 1.4% of Argent Trust Co's holdings, making the stock its 12th largest position. Argent Trust Co's holdings in Johnson & Johnson were worth $48,597,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. Silver Coast Investments LLC increased its stake in Johnson & Johnson by 3.8% in the 2nd quarter. Silver Coast Investments LLC now owns 1,066 shares of the company's stock worth $271,000 after acquiring an additional 39 shares during the last quarter. Townsend Asset Management Corp NC ADV increased its position in shares of Johnson & Johnson by 0.6% in the second quarter. Townsend Asset Management Corp NC ADV now owns 6,418 shares of the company's stock worth $1,630,000 after purchasing an additional 39 shares during the last quarter. Sierra Capital LLC lifted its position in Johnson & Johnson by 0.5% during the fourth quarter. Sierra Capital LLC now owns 8,144 shares of the company's stock valued at $1,685,000 after purchasing an additional 41 shares during the last quarter. Beaird Harris Wealth Management LLC grew its stake in Johnson & Johnson by 1.8% in the 4th quarter. Beaird Harris Wealth Management LLC now owns 2,422 shares of the company's stock worth $501,000 after buying an additional 42 shares in the last quarter. Finally, Ballast Advisors LLC raised its position in shares of Johnson & Johnson by 1.2% during the 1st quarter. Ballast Advisors LLC now owns 3,598 shares of the company's stock valued at $879,000 after buying an additional 42 shares in the last quarter. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Trading Up 1.0%

Shares of JNJ opened at $268.30 on Friday. Johnson & Johnson has a 1 year low of $173.33 and a 1 year high of $276.47. The company has a 50 day simple moving average of $258.88 and a two-hundred day simple moving average of $243.94. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.09 and a quick ratio of 0.81. The firm has a market cap of $646.58 billion, a P/E ratio of 31.09, a price-to-earnings-growth ratio of 2.54 and a beta of 0.24.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.84 by $0.06. The company had revenue of $25.31 billion during the quarter, compared to analysts' expectations of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. Johnson & Johnson's quarterly revenue was up 6.6% on a year-over-year basis. During the same period last year, the company posted $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, equities analysts expect that Johnson & Johnson will post 11.61 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th will be issued a $1.34 dividend. The ex-dividend date of this dividend is Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.0%. Johnson & Johnson's dividend payout ratio (DPR) is presently 62.11%.

Analyst Upgrades and Downgrades

JNJ has been the topic of a number of research reports. Argus set a $300.00 price target on Johnson & Johnson in a research report on Wednesday, July 29th. Freedom Capital upgraded shares of Johnson & Johnson from a "hold" rating to a "strong-buy" rating in a research report on Thursday, July 16th. Morgan Stanley boosted their price objective on shares of Johnson & Johnson from $284.00 to $294.00 and gave the stock an "overweight" rating in a report on Thursday, July 16th. Scotiabank reissued an "outperform" rating and issued a $305.00 target price on shares of Johnson & Johnson in a research note on Thursday, July 16th. Finally, TD Cowen raised their price target on Johnson & Johnson from $250.00 to $300.00 and gave the stock a "buy" rating in a research report on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $268.22.

Insider Buying and Selling

In other news, EVP Vanessa Broadhurst sold 23,054 shares of Johnson & Johnson stock in a transaction that occurred on Monday, July 20th. The stock was sold at an average price of $251.27, for a total value of $5,792,778.58. Following the completion of the transaction, the executive vice president owned 23,003 shares in the company, valued at approximately $5,779,963.81. The trade was a 50.06% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Kathryn E. Wengel sold 10,000 shares of the stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total value of $2,411,500.00. Following the sale, the executive vice president owned 114,288 shares in the company, valued at $27,560,551.20. The trade was a 8.05% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 63,972 shares of company stock valued at $16,245,605. Insiders own 0.16% of the company's stock.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: China approved J&J’s oral psoriasis pill, Icotyde, expanding the company’s immunology portfolio and giving it a simpler treatment option to compete with rival products from Bristol Myers Squibb and AbbVie. The pill could also broaden J&J’s presence in China, although it may compete with the company’s established injectable Tremfya franchise. China approves J&J's oral psoriasis pill
• Positive Sentiment: The FDA expanded approval of Imaavy for warm autoimmune hemolytic anemia in patients 12 and older who are receiving or have previously received steroids. As the first approved treatment for this rare, potentially life-threatening disorder, Imaavy addresses an unmet need and could support J&J’s rare-disease growth strategy. Imaavy expands into rare blood disorder
• Positive Sentiment: Recent analysis points to a favorable shift in J&J’s product mix, with newer products increasingly offsetting pressure from the STELARA patent loss. This supports the view that growth in the broader Innovative Medicine portfolio may be more important than the shrinking contribution from STELARA. Did a product swap fuel JNJ stock's surge?
• Positive Sentiment: Investors continue to view JNJ as a defensive dividend holding, supported by its balance sheet, diversified healthcare operations and ability to generate dependable returns through economic cycles. Johnson & Johnson is a top dividend stock

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source